Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dosimetric impact of radiofrequency tumor treating field arrays on dose on surface and at depth.

Journal of applied clinical medical physics·2026

Same author

Ethical and Clinical Boundaries in Genomics & Newborn Screening: A Brief Report from IPIC2025.

International journal of neonatal screening·2026

Same author

Bifidobacterium pseudocatenulatum capsular exopolysaccharide enhances systemic anti-tumour immunity in pre-clinical breast cancer.

Research square·2026

Same author

Accurate and fast event-based shape measurement of mixed reflectance scenes.

Nature communications·2026

Same author

Costs of Treating Uncomplicated Sickle Cell Complications in a Day Hospital Setting in Equatorial Africa.

Anemia·2026

Same author

Correction: Combined endoscopic and robotic-assisted transcolonic polypectomy as a novel technique for challenging polyp resection.

Surgical endoscopy·2025

Search research articles

Related Experiment Video

Updated: May 27, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Bromocriptine: its place in type 2 diabetes Tx.

Karen R Sando¹, James Taylor

¹College of Pharmacy, Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, USA. ksando@cop.ufl.edu

The Journal of Family Practice

|November 4, 2011

Summary

Bromocriptine offers a treatment option for patients with type 2 diabetes who cannot tolerate other medications or need only slight improvements in their A1c levels.

Related Experiment Videos

Last Updated: May 27, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Area of Science:

Endocrinology
Metabolic Disorders

Background:

Type 2 diabetes mellitus (T2DM) management requires diverse therapeutic options.
Patient adherence and tolerability are critical factors in diabetes pharmacotherapy.
Achieving target glycemic control, including hemoglobin A1c (HbA1c) levels, is essential for preventing long-term complications.

Purpose of the Study:

To evaluate the efficacy and tolerability of bromocriptine in patients with type 2 diabetes.
To identify patient subgroups who may particularly benefit from bromocriptine therapy.

Main Methods:

A review of clinical studies investigating bromocriptine for T2DM was conducted.
Data on glycemic control (HbA1c), patient-reported tolerability, and adverse events were analyzed.

Main Results:

Bromocriptine demonstrated a modest reduction in HbA1c levels in specific patient populations.
Patients intolerant to other antidiabetic agents showed potential benefit.
The medication was generally well-tolerated, with a favorable side effect profile for those needing minimal HbA1c reduction.

Conclusions:

Bromocriptine can be a valuable therapeutic option for select patients with type 2 diabetes.
Its utility is particularly noted in individuals with medication intolerances or those requiring only minor glycemic improvements.